Circulating free testosterone and risk of aggressive prostate cancer: Prospective and Mendelian randomisation analyses in international consortia

Previous studies had limited power to assess the associations of testosterone with aggressive disease as a primary endpoint. Further, the association of genetically predicted testosterone with aggressive disease is not known. We investigated the associations of calculated free and measured total testosterone and sex hormone‐binding globulin (SHBG) with aggressive, overall and early‐onset prostate cancer. In blood‐based analyses, odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression from prospective analysis of biomarker concentrations in the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group (up to 25 studies, 14 944 cases and 36 752 controls, including 1870 aggressive prostate cancers). In Mendelian randomisation (MR) analyses, using instruments identified using UK Biobank (up to 194 453 men) and outcome data from PRACTICAL (up to 79 148 cases and 61 106 controls, including 15 167 aggressive cancers), ORs were estimated using the inverse‐variance weighted method. Free testosterone was associated with aggressive disease in MR analyses (OR per 1 SD = 1.23, 95% CI = 1.08‐1.40). In blood‐based analyses there was no association with aggressive disease overall, but there was heterogeneity by age at blood collection (OR for men aged <60 years 1.14, CI = 1.02‐1.28; Phet = .0003: inverse association for older ages). Associations for free testosterone were positive for overall prostate cancer (MR: 1.20, 1.08‐1.34; blood‐based: 1.03, 1.01‐1.05) and early‐onset prostate cancer (MR: 1.37, 1.09‐1.73; blood‐based: 1.08, 0.98‐1.19). SHBG and total testosterone were inversely associated with overall prostate cancer in blood‐based analyses, with null associations in MR analysis. Our results support free testosterone, rather than total testosterone, in the development of prostate cancer, including aggressive subgroups.

[1]  G. Davey Smith,et al.  Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development , 2020, Nature Reviews Cardiology.

[2]  T. Key,et al.  Circulating insulin‐like growth factor‐I, total and free testosterone concentrations and prostate cancer risk in 200 000 men in UK Biobank , 2020, International journal of cancer.

[3]  James R. Staley,et al.  A robust and efficient method for Mendelian randomization with hundreds of genetic variants , 2020, Nature Communications.

[4]  M. McCarthy,et al.  Using human genetics to understand the disease impacts of testosterone in men and women , 2020, Nature Medicine.

[5]  Frank Dudbridge,et al.  Guidelines for performing Mendelian randomization investigations , 2019, Wellcome open research.

[6]  T. Key,et al.  Hormone‐related diseases and prostate cancer: An English national record linkage study , 2019, International journal of cancer.

[7]  Bogdan Pasaniuc,et al.  Identification of novel susceptibility loci and genes for prostate cancer risk: A transcriptome-wide association study in over 140,000 European descendants. , 2019, Cancer research.

[8]  Stephen Burgess,et al.  PhenoScanner V2: an expanded tool for searching human genotype–phenotype associations , 2019, Bioinform..

[9]  Sonja A Swanson,et al.  Interpretation and Potential Biases of Mendelian Randomization Estimates With Time-Varying Exposures. , 2018, American journal of epidemiology.

[10]  E. Metter,et al.  Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies , 2018, European urology.

[11]  K. D. Sørensen,et al.  Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci , 2018, Nature Genetics.

[12]  H. Cohen,et al.  Lessons From the Testosterone Trials , 2018, Endocrine reviews.

[13]  B. Neale,et al.  Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases , 2018, Nature Genetics.

[14]  S. Lewis,et al.  Causal Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization? , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[15]  A. Whittemore,et al.  Circulating sex hormones in relation to anthropometric, sociodemographic and behavioural factors in an international dataset of 12,300 men , 2017, PloS one.

[16]  N. Sharifi,et al.  Androgen Signaling in Prostate Cancer. , 2017, Cold Spring Harbor perspectives in medicine.

[17]  Frederick C W Wu,et al.  A Reappraisal of Testosterone's Binding in Circulation: Physiological and Clinical Implications. , 2017, Endocrine reviews.

[18]  David Handelsman.  Free Testosterone: Pumping up the Tires or Ending the Free Ride? , 2017, Endocrine reviews.

[19]  S. Thompson,et al.  Interpreting findings from Mendelian randomization using the MR-Egger method , 2017, European Journal of Epidemiology.

[20]  Stephen Burgess,et al.  Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants , 2016, Epidemiology.

[21]  Debbie A Lawlor,et al.  Triangulation in aetiological epidemiology , 2016, International journal of epidemiology.

[22]  T. Littlejohns,et al.  Lifestyle factors and prostate-specific antigen (PSA) testing in UK Biobank: Implications for epidemiological research , 2016, Cancer epidemiology.

[23]  I. Thompson,et al.  Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  N. Sheehan,et al.  Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic , 2016, International journal of epidemiology.

[25]  L. Ferrucci,et al.  A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. , 2016, Cancer research.

[26]  G. Davey Smith,et al.  Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator , 2016, Genetic epidemiology.

[27]  J. Bowden,et al.  Integrating summarized data from multiple genetic variants in Mendelian randomization: bias and coverage properties of inverse-variance weighted methods , 2015, 1512.04486.

[28]  R. Kacker,et al.  Free testosterone by direct and calculated measurement versus equilibrium dialysis in a clinical population , 2013, The aging male : the official journal of the International Society for the Study of the Aging Male.

[29]  Ian M Thompson,et al.  Long-term survival of participants in the prostate cancer prevention trial. , 2013, The New England journal of medicine.

[30]  Hong-Yo Kang.  Beyond the male sex hormone: deciphering the metabolic and vascular actions of testosterone. , 2013, The Journal of endocrinology.

[31]  G. Colditz,et al.  Prostate cancer: is it time to expand the research focus to early-life exposures? , 2013, Nature Reviews Cancer.

[32]  M. Pollak.  The insulin and insulin-like growth factor receptor family in neoplasia: an update , 2012, Nature Reviews Cancer.

[33]  M. Blankenstein,et al.  Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer , 2012, BJU international.

[34]  A. Morgentaler,et al.  Comparison of free testosterone results by analog radioimmunoassay and calculated free testosterone in an ambulatory clinical population. , 2010, The journal of sexual medicine.

[35]  D. Tindall,et al.  Effect of dutasteride on the risk of prostate cancer. , 2010, The New England journal of medicine.

[36]  T. Key,et al.  Pooling Biomarker Data from Different Studies of Disease Risk, with a Focus on Endogenous Hormones , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[37]  David Handelsman,et al.  ORIGINAL ARTICLE: Accuracy of calculated free testosterone formulae in men , 2010, Clinical endocrinology.

[38]  Yan Liu,et al.  Risk factors for prostate cancer incidence and progression in the health professionals follow‐up study , 2007, International journal of cancer.

[39]  P. Gann,et al.  Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. , 2007, Journal of the National Cancer Institute.

[40]  I. Thompson,et al.  Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. , 2006, Journal of the National Cancer Institute.

[41]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[42]  E. Metter,et al.  Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. , 2001, The Journal of clinical endocrinology and metabolism.

[43]  A. Vermeulen,et al.  A critical evaluation of simple methods for the estimation of free testosterone in serum. , 1999, The Journal of clinical endocrinology and metabolism.

[44]  R. Collins,et al.  Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. , 1999, American journal of epidemiology.

[45]  M. Wheeler,et al.  The Determination of Bio-Available Testosterone , 1995, Annals of clinical biochemistry.

[46]  W. Bartsch.  Interrelationships between sex hormone-binding globulin and testosterone, 5 alpha-dihydrotestosterone and oestradiol-17 beta in blood of normal men. , 1980, Maturitas.

[47]  P. D. Semple.  KLINEFELTER'S SYNDROME , 1977, The Medical journal of Australia.

[48]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.